Vancomycin therapeutics and monitoring: a contemporary approach

Contribution of Selected Gene Mutations to Resistance in Clinical Isolates of Vancomycin-Intermediate Staphylococcus aureus

(2012) Cory Hafer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis

(2012) S. J. van Hal et al.   CLINICAL INFECTIOUS DISEASES

Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study

(2012) R. G. Wunderink et al.   CLINICAL INFECTIOUS DISEASES

Relationship between Vancomycin-Resistant Staphylococcus aureus, Vancomycin-Intermediate S. aureus, High Vancomycin MIC, and Outcome in Serious S. aureus Infections

(2012) N. E. Holmes et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient Cohort

(2012) Ravina Kullar et al.   PHARMACOTHERAPY

Vancomycin-Induced Neutropenia: Is it Dose- or Duration-Related?

(2011) Emily Black et al.   ANNALS OF PHARMACOTHERAPY

Evaluation of the Accuracy of a Pharmacokinetic Dosing Program in Predicting Serum Vancomycin Concentrations in Critically Ill Patients

(2011) C. Aubron et al.   ANNALS OF PHARMACOTHERAPY

Vancomycin Dosing: Assessment of Time to Therapeutic Concentration and Predictive Accuracy of Pharmacokinetic Modeling Software

(2011) Maya O Nunn et al.   ANNALS OF PHARMACOTHERAPY

walKandclpPMutations Confer Reduced Vancomycin Susceptibility inStaphylococcus aureus

(2011) Mitsutaka Shoji et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection

(2011) Milagros Gonzales et al.   BMC INFECTIOUS DISEASES

An Association Between Bacterial Genotype Combined With a High-Vancomycin Minimum Inhibitory Concentration and Risk of Endocarditis in Methicillin-Resistant Staphylococcus aureus Bloodstream Infection

(2011) Clare E. Miller et al.   CLINICAL INFECTIOUS DISEASES

Predicting High Vancomycin Minimum Inhibitory Concentration in Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

(2011) A. S. Lubin et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES

New Gram-positive antibiotics

(2011) Sebastiaan J. van Hal et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Vancomycin dosing and monitoring 2 years after the guidelines

(2011) Ben M Lomaestro   Expert Review of Anti-Infective Therapy

Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity

(2011) M. L. Avent et al.   INTERNAL MEDICINE JOURNAL

Antibiotic Choice May Not Explain Poorer Outcomes in Patients With Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations

(2011) Natasha E. Holmes et al.   JOURNAL OF INFECTIOUS DISEASES

Validation of the Effectiveness of a Vancomycin Nomogram in Achieving Target Trough Concentrations of 15–20 mg/L Suggested by the Vancomycin Consensus Guidelines

(2011) Ravina Kullar et al.   PHARMACOTHERAPY

Vancomycin Heteroresistance Is Associated with Reduced Mortality in ST239 Methicillin-Resistant Staphylococcus aureus Blood Stream Infections

(2011) Sebastiaan J. van Hal et al.   PLoS One

Vancomycin Dosing in Patients on Intermittent Hemodialysis

(2011) Stefaan J. Vandecasteele et al.   SEMINARS IN DIALYSIS

Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-IntermediateStaphylococcus aureusIsolates

(2010) Sebastiaan J. van Hal et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

(2010) B. P. Howden et al.   CLINICAL MICROBIOLOGY REVIEWS

Use of Vancomycin in Pediatrics

(2010) Walter Dehority   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health‐System Pharmacists, and the Society of Infectious Diseases Pharmacists

(2009) Michael J. Rybak et al.   CLINICAL INFECTIOUS DISEASES

Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies

(2009) P. A. Moise et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Features of Heteroresistant Vancomycin-IntermediateStaphylococcus aureusBacteremia versus Those of Methicillin-ResistantS. aureusBacteremia

(2009) Yasmin Maor et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation and Comparison of Simple Multiple Model, Richer Data Multiple Model, and Sequential Interacting Multiple Model (IMM) Bayesian Analyses of Gentamicin and Vancomycin Data Collected From Patients Undergoing Cardiothoracic Surgery

(2009) Iona Macdonald et al.   THERAPEUTIC DRUG MONITORING

Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia

(2008) T. P. Lodise et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY